Top 10 Healthcare Equipment Stocks To Watch For 2014

Source: J. Greenstein & Co.

Jonathan Greenstein considers himself "The Indiana Jones of Judaica." His adventures in tracking down valuable antiques have unearthed such treasures as a $100,000 menorah and a spice box worth $500,000, and a Torah shield that the owner thought might be worth $50, but turned out to be valued at more than half a million dollars.

Greenstein is the owner of the only auction house in the country devoted solely to the sale of Jewish ritual objects. He says he gets 25 to 50 emails every week from people who want to know if their grandmother's menorah or Kiddush cup is valuable.

Many times, families assume that the only value their memorabilia has is sentimental. Nothing could be further from the truth.

Top 10 Healthcare Equipment Stocks To Watch For 2014: Blackrock Debt Strategies Fund Inc. (DSU)

BlackRock Debt Strategies Fund, Inc. is a closed ended fixed income mutual fund launched by BlackRock, Inc. The fund is co managed by BlackRock Advisors, LLC and BlackRock Financial Management, Inc. It invests in the public fixed income markets of the United States. The fund invests in the securities of companies operating across diversified sectors. It primarily invests in High Yield and corporate bonds with an average credit rating of Ba or lower by Moody's Investors Service, Inc. The fund was formerly known as Debt Strategies Fund Inc. BlackRock Debt Strategies Fund, Inc. was formed on March 27, 1998 and is domiciled in the United States.

Top 10 Healthcare Equipment Stocks To Watch For 2014: New York Community Bancorp Inc.(NYB)

New York Community Bancorp, Inc. operates as a multi-bank holding company for New York Community Bank and New York Commercial Bank, which offer banking products and services in New York, New Jersey, Ohio, Florida, and Arizona. It primarily engages in generating deposits and originating loans. The company?s deposit products include checking and savings accounts, certificates of deposit, individual retirement accounts, NOW and money market accounts, and non-interest-bearing demand deposit accounts. Its lending portfolio comprises one- to four-family loans; multi-family loans; commercial real estate loans; acquisition, development, and construction loans; home equity lines of credit; commercial and industrial loans; and consumer loans. New York Community Bancorp also provides installment loans, revolving lines of credit, cash management, online banking, automated teller machine, and phone banking services. The company serves small and mid-size businesses, professional associ ations, government agencies, consumers, and school districts. As of June 30, 2011, it operated 242 community bank branches, 34 commercial bank branches, and 286 ATM locations. The company was formerly known as Queens County Bancorp, Inc. and changed its name to New York Community Bancorp, Inc. in November 2000. New York Community Bancorp, Inc. was founded in 1859 and is based in Westbury, New York.

5 Best Stocks To Own Right Now: The Connecticut Bank and Trust Company(CTBC)

The Connecticut Bank and Trust Company provides commercial banking products and services in Connecticut. It accepts various interest bearing and noninterest bearing accounts with a range of maturity date options, including commercial and retail checking accounts, money market accounts, individual retirement accounts, savings accounts, certificates of deposit, and sweep accounts. The company?s loan portfolio comprises commercial, commercial real estate, construction, consumer and installment, and residential real estate loans. It also provides cash management services; courier service; sweep and client escrow accounts; direct deposit of payroll and social security checks; online banking; CBT Surepay; wire transfers, automated clearinghouse, and electronic data interchange services; debit cards; merchant credit card processing; and automated teller machine services. In addition, the company offers third party products and services consisting of fiduciary services, investmen t management, and stock brokerage services, as well as insurance products, including commercial and personal lines, and payroll processing. It serves privately-owned businesses and individuals, including attorneys, accountants and physicians, manufacturing companies, service companies, and commercial real estate developers. The company offers its products and services through seven offices located in Hartford, Glastonbury, Vernon, Newington, Windsor, and Rocky Hill. The Connecticut Bank and Trust Company was founded in 2004 and is based in Hartford, Connecticut.

Top 10 Healthcare Equipment Stocks To Watch For 2014: Sin Heng Heavy Machinery Ltd (KF4.SI)

Sin Heng Heavy Machinery Limited, together with its subsidiaries, operates as a heavy lifting service provider, focusing on the mid-to-high lifting capacity segment. It engages in the rental of cranes, aerial lifts, and other heavy lifting equipment; and trade of new and used cranes and aerial lifts, as well as sale and distribution of related spare parts. The company also undertakes turnkey project engineering services; and offers facilities and custody services. Its fleet includes crawler, all terrain, truck, and rough terrain cranes, as well as boom and scissor lifts. The company serves customers in various industries, such as infrastructure and geotechnic, construction, offshore and marine, and oil and gas industries primarily in Singapore, Indonesia, the Middle East, Malaysia, Vietnam, India, and Brunei. The company was founded in 1969 and is based in Singapore.

Top 10 Healthcare Equipment Stocks To Watch For 2014: Nomura Holdings Inc ADR (NMR)

Nomura Holdings, Inc. provides financial services in Japan and internationally. The company operates in three divisions: Retail, Asset Management, and Wholesale. The Retail division primarily offers investment consultation services to retail clients. It also provides various financial instruments, such as stocks, debt securities, investment trusts, and variable annuity insurance products for the short, medium, and long term. As of March 31, 2011, this division operated a network of approximately 174 branches. The Asset Management division involves in the development and management of investment trusts. This division also offers investment advisory services to public and private pensions, governments and their agencies, central banks, and institutional investors. The Wholesale division engages in the fixed income and equity trading, and asset finance businesses. It provides debt securities, foreign currencies, and stocks, as well as related derivatives; and equities securit ies and equity-linked derivatives; and execution services, such as algorithmic trading and transaction cost analysis. This division also involves in underwriting various types of stocks, convertible and exchangeable securities, investment grade debt, sovereign and emerging market debt, high yield debt, structured securities, and other securities; offers financial advisory services and solutions on business transactions, including mergers and acquisitions, divestitures, spin-offs, capital structuring, corporate defense activities, leveraged buyouts, and risk solutions; and operates private equity investment business. The company primarily serves individuals, corporations, financial institutions, governments, and governmental agencies, as well as retail and asset management clients. Nomura Holdings, Inc. was founded in 1925 and is headquartered in Tokyo, Japan.

Top 10 Healthcare Equipment Stocks To Watch For 2014: Atac Resources Ltd. (ATC.V)

ATAC Resources Ltd. engages in exploring for metals and minerals with a focus on gold in Canada. It primarily focuses on the exploration and development of the Rackla gold project covering approximately 1,600 square kilometers located in central Yukon. The company also owns interests in the Connaught prospect, a silver-gold property located in the Sixtymile placer gold camp of western Yukon Territory; and the Dawson gold project located in west-central Yukon approximately. ATAC Resources Ltd. is headquartered in Vancouver, Canada.

Top 10 Healthcare Equipment Stocks To Watch For 2014: Cell Therapeutics Inc (CTIC)

Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.

Pixuvri

As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.

OPAXIO

OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.

Tosedostat

In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.

Brostallicin

As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).

The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.

Top 10 Healthcare Equipment Stocks To Watch For 2014: Questcor Pharmaceuticals Inc.(QCOR)

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides prescription drugs for the treatment of auto-immune diseases. The company?s primary product is H.P. Acthar Gel (repository corticotropin injection), an injectable drug for the treatment of acute exacerbations of multiple sclerosis; infantile spasms in infants and children under two years of age; nephrotic syndrome; and Lupus. Questcor Pharmaceuticals, Inc. was founded in 1990 and is headquartered in Anaheim, California.

Top 10 Healthcare Equipment Stocks To Watch For 2014: TAL Education Group(XRS)

TAL Education Group, together with its subsidiaries, provides K-12 after-school tutoring services in the People?s Republic of China. It offers tutoring services to K-12 students covering various academic subjects, including mathematics, English, Chinese, physics, chemistry, and biology. The company provides tutoring services through small classes; personalized premium services, such as one-on-one tutoring; and online course offerings. As of May 31, 2011, it operated a network of 199 physical learning centers in Beijing, Shanghai, Guangzhou, Shenzhen, Tianjin, Wuhan, Nanjing, Hangzhou, Chengdu, and Xi?an; and eduu.com, an online education platform for online courses. The company also offers education and management consulting services, as well as sells software. It operates under the Xueersi brand. The company was founded in 2003 and is headquartered in Beijing, China.

Top 10 Healthcare Equipment Stocks To Watch For 2014: Tri-Tech Holding Inc.(TRIT)

Tri-Tech Holding Inc. provides integrated solutions to water resource management and environmental protection industries in the People?s Republic of China. It provides services in the fields of environmental protection; and water resource monitoring, development, utilization, and protection to the government agencies, municipalities, and industrial companies. The company operates in three segments: Water, Wastewater Treatment, and Municipal Infrastructure; Water Resource Management System and Engineering Services; and Industrial Pollution Control and Safety. The Water, Wastewater Treatment, and Municipal Infrastructure segment includes projects involving municipal water supply and distribution, wastewater treatment and gray water reuse engineering, procurement, and construction; build and transfer; proprietary process control systems; process equipment integration and proprietary odor control systems; and other municipal facilities engineering, operation management, and r elated infrastructure construction projects. The Water Resource Management System and Engineering Services segment includes projects relating to water resource protection and allocation, flood control and forecasting, irrigation systems, system integration, proprietary hardware and software products, and related ventures. The Industrial Pollution Control and Safety segment comprises systems for volatile organic compound abatement; odor control; water and wastewater treatment; the design, engineering, procurement, and construction of water recycling facilities for oil, gas, petrochemical, and power industries; and safety and clean production technologies for oil and gas exploration and pipeline. The company is headquartered in Beijing, the People?s Republic of China.